Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
399.9 USD | +1.43% | +0.64% | -1.71% |
Apr. 18 | Vertex Pharmaceuticals Says FDA Granted Rolling Review of Suzetrigine to Treat Acute Pain | MT |
Apr. 17 | UBS Adjusts Vertex Pharmaceuticals Price Target to $466 From $498, Maintains Buy Rating | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-1.71% | 103B | |
+2.49% | 96.73B | |
-0.29% | 21.31B | |
-16.61% | 21.21B | |
-5.20% | 18.79B | |
-42.14% | 16.37B | |
-27.40% | 13.68B | |
+1.44% | 13.44B | |
+21.29% | 10.98B | |
-21.79% | 8.56B |
- Stock Market
- Equities
- VRTX Stock
- News Vertex Pharmaceuticals Incorporated
- Vertex Pharmaceuticals : Piper Sandler Adjusts Price Target on Vertex Pharmaceuticals to $261 From $347, Maintains Overweight Rating